article · One Health Bulletin
Objective: To detect the presence of extended-spectrum beta-lactamase-producing Gram-negative bacteria in water from selected storage tanks in Ogun State, Nigeria. Methods: MacConkey agar supplemented with 6 pg/mL of cefotaxime was used to isolate bacteria. Pure isolates were identified through PCR amplification. The susceptibility patterns of the isolates to ceftazidime (30 μg/mL), amoxicillin/clavulanate (30 μg/mL), tetracycline (30 μg/mL), cefotaxime (30 μg/mL), cefpodoxime (10 μg/mL), and ciprofloxacin (5 μg/mL) were evaluated using the Kirby-Bauer disc diffusion method, while the identification of beta-lactamase production was performed using the double disc synergy test. Results: A total of 19 isolates belonging to four genera ( Citrobacter, Pseudomonas, Escherichia , and Serratia ) were obtained from the ten water samples. Escherichia coli and Citrobacter spp. had the highest presence (30.0%). The antibiotic with highest resistance was observed to be cefpodoxime (100%) followed by amoxicillin/clavulanate (89.5%) and cefotaxime (89.5%), the least was noted with tetracycline (31.6%). Additionally, 10 (52.6%) out of the 19 isolates showed beta-lactamase-producing phenotypic properties with high resistance to cefpodoxime (100%), amoxicillin/clavulanate (100%) and ceftazidime (90.0%). Additionally, this study showed the link between bacterial strains identified by 16S rRNA and related human diseases, highlighting the importance of genetic identification in managing infections. Conclusions: This study highlights the prevalence of beta-lactam-resistant bacteria, emphasizing the urgent need for proactive measures to address this issue.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4103/ohbl.ohbl_38_24
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.